Critical Outcome Technologies Inc Announces Positive Results From Experiments Carried Out With Lead Cancer Drug Candidate, COTI-2


Tuesday, 11 Jun 2013 07:00am EDT 

Critical Outcome Technologies Inc announced positive results from experiments carried out with its lead cancer drug candidate, COTI-2, in the cancer research laboratories of Gordon Mills, M.D., Ph.D. Chair of the Department of Systems Biology and the Co-director of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center in Houston, Texas. These preclinical experiments were designed to definitively determine the effect of COTI-2 in 32 common p53 mutations. The p53 gene is a tumor suppressing gene. However, if the p53 gene is mutated, cancers often develop and grow out of control. Extensive data from the experiments have demonstrated that: (i) COTI-2 has a major mechanism of action that is dependent on p53 gene mutation status in human cancer cells. This is of significant therapeutic importance because at least 50% of all human cancers have at least one type of p53 mutation; (ii) COTI-2 restores p53 protein to its normal function in human cancer cells with a wide range of common p53 gene mutations. This range includes three of the most common mutations found in about 20% of all human cancers; (iii) COTI-2 is also effective in the presence of common mutations in the PI3K/AKT/mTOR cell signaling pathway. This means that COTI-2 is effective in cancers with mutations that lead to over expression of the tumor promoting protein AKT. 

Company Quote

0.3
-0.015 -4.76%
19 Sep 2014